At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SXTP 60 degrees pharmaceuticals, Inc.
Trading 09-09 15:48:06 EDT
0.9650
-0.0118
-1.21%
High0.9800Low0.9300Vol28.21K
Open0.9800D1 Closing0.9768Amplitude5.12%
Mkt Cap3.39MTradable Cap1.71MTotal Shares3.52M
T/O26.70KT/O Rate1.59%Tradable Shares1.77M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

60 Degrees Pharmaceuticals Updates Strategy for Tick-Borne Diseases
TIPRANKS  ·  09-09 05:07
60 Degrees Pharmaceuticals Updates Strategy for Tick-Borne Diseases
60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire  ·  09-03
60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference
Analysts’ Opinions Are Mixed on These Healthcare Stocks: OmniAb (OABI), Bicycle Therapeutics (BCYC) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
TIPRANKS  ·  08-17
Analysts’ Opinions Are Mixed on These Healthcare Stocks: OmniAb (OABI), Bicycle Therapeutics (BCYC) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
60 Degrees Pharmaceuticals Q2 EPS USD -0.9
THOMSON REUTERS  ·  08-15
60 Degrees Pharmaceuticals Q2 EPS USD -0.9
60 Degrees Pharmaceuticals Q2 Operating Expenses USD 2.33 Million
THOMSON REUTERS  ·  08-15
60 Degrees Pharmaceuticals Q2 Operating Expenses USD 2.33 Million
Press Release: 60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
Dow Jones  ·  08-15
Press Release: 60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
60 Degrees Pharma Q2 FY26 Net Loss Widens 30.6% to $2.26 Million; Revenue More than Doubles to $207,898
Reuters  ·  08-15
60 Degrees Pharma Q2 FY26 Net Loss Widens 30.6% to $2.26 Million; Revenue More than Doubles to $207,898
60 Degrees Pharmaceuticals Holds Annual Shareholder Meeting
Reuters  ·  08-07
60 Degrees Pharmaceuticals Holds Annual Shareholder Meeting
60 Degrees Pharmaceuticals Issues Series A, Series B Warrants Exercisable at $1.49 in $1 Million Private Placement
Reuters  ·  08-05
60 Degrees Pharmaceuticals Issues Series A, Series B Warrants Exercisable at $1.49 in $1 Million Private Placement
60 Degrees Pharmaceuticals Completes Private Placement to Raise Capital
TIPRANKS  ·  08-05
60 Degrees Pharmaceuticals Completes Private Placement to Raise Capital
60 Degrees Pharmaceuticals to sell shares and warrants in private placement
TIPRANKS  ·  07-31
60 Degrees Pharmaceuticals to sell shares and warrants in private placement
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced at-the-Market Under NASDAQ Rules
THOMSON REUTERS  ·  07-31
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced at-the-Market Under NASDAQ Rules
60 Degrees Pharma Hits Minimum Enrollment Trigger for Interim Readout in Severe Babesiosis Tafenoquine Trial
Reuters  ·  07-30
60 Degrees Pharma Hits Minimum Enrollment Trigger for Interim Readout in Severe Babesiosis Tafenoquine Trial
60 Degrees Pharmaceuticals Files Form 3 Showing Knight Therapeutics Stake of 658,629 Shares
Reuters  ·  07-30
60 Degrees Pharmaceuticals Files Form 3 Showing Knight Therapeutics Stake of 658,629 Shares
60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026
THOMSON REUTERS  ·  07-30
60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026
60 Degrees Pharmaceuticals - Company to Request FDA Meeting on Nda Pathway for Tafenoquine in Babesiosis
THOMSON REUTERS  ·  07-30
60 Degrees Pharmaceuticals - Company to Request FDA Meeting on Nda Pathway for Tafenoquine in Babesiosis
60 Degrees updates strategy for ARAKODA and profitability
TIPRANKS  ·  07-21
60 Degrees updates strategy for ARAKODA and profitability
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-borne Diseases
THOMSON REUTERS  ·  07-08
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-borne Diseases
60 Degrees Pharma Says DSMB Backs Continuing Phase 2 Tafenoquine Chronic Babesiosis Fatigue Study
Reuters  ·  07-01
60 Degrees Pharma Says DSMB Backs Continuing Phase 2 Tafenoquine Chronic Babesiosis Fatigue Study
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-free Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
THOMSON REUTERS  ·  07-01
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-free Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue

Introduction

Company Name.
60 degrees pharmaceuticals, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is based in Washington, District Of Columbia.
Issue price:
--